首页> 外文期刊>Current opinion in urology >Modern pharmacotherapy for erectile dysfunction: evolving concepts with central and peripheral acting agents.
【24h】

Modern pharmacotherapy for erectile dysfunction: evolving concepts with central and peripheral acting agents.

机译:勃起功能障碍的现代药物疗法:不断发展的中枢和外周作用剂概念。

获取原文
获取原文并翻译 | 示例
       

摘要

Pharmacotherapy for men experiencing erectile dysfunction has undergone dramatic advances over the past 5 years with the introduction of an effective oral agent. Sildenafil has increased the pool of couples seeking treatment for this important health issue as well as expanding the numbers of physicians treating it. Research into the growing field of erectile dysfunction is expanding at a rapid pace. Independent investigators worldwide now regularly contribute to our body of scientific knowledge. Novel oral therapies targeted at specific points along the erectile cascade are undergoing pre-clinical and early phase registration trials with the promise of rapid action, extended duration of responsiveness and an improved side effect profile. In this review, we have highlighted recent information on the next generation of phosphodiesterase inhibitors and summarized the evolving research into centrally acting agents, which may lead to effective combination therapy.
机译:在过去的5年中,针对男性勃起功能障碍的药物治疗已经取得了巨大进步,其中引入了一种有效的口服药物。西地那非增加了为这一重要健康问题寻求治疗的夫妇的人数,并扩大了治疗该病的医生人数。对勃起功能障碍不断发展的领域的研究正在迅速发展。现在,世界各地的独立调查人员定期为我们的科学知识做出贡献。针对勃起级联特定点的新型口服疗法正在进行临床前和早期阶段的注册试验,有望迅速采取行动,延长反应时间,并改善副作用。在这篇综述中,我们重点介绍了下一代磷酸二酯酶抑制剂的最新信息,并总结了正在发展的中枢作用药物研究,这可能导致有效的联合治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号